
One Star Is Orbiting Inside Another in This Never-Before-Seen Binary System
For the first time, astronomers have spotted a rapidly spinning neutron star that is gravitationally bound to a helium star companion. The discovery of this unusual binary system helps confirm a long theorized—but rarely seen—cosmic process called common envelope evolution.
Binary star systems, or pairs of stars that orbit around each other, are very common. In fact, it's estimated that 85% of stars in the universe have at least one companion. But this newly discovered pair is unlike any seen before.
In this case, a helium star is bound to a millisecond pulsar: a fast-spinning neutron star that emits beams of radiation at regular intervals. These stars achieve their extraordinary rotation rates by siphoning matter from nearby stellar companions.
In May 2020, a team of researchers led by Jin Lin Han, a radio astronomer at the National Astronomical Observatories and the Chinese Academy of Sciences in Beijing, used China's FAST radio telescope to detect weak signals from a point deep within the Milky Way galaxy.
A few months later, the researchers confirmed that these signals were radiation emissions from a pulsar. They then tracked these bursts for four and a half years, and their measurements revealed that this star isn't alone. It's actually part of a binary system, orbiting its companion every 3.6 hours. But for one-sixth of that orbit, the pulsar's radiation is blocked—or eclipsed—by its companion.
'That's a large part of the orbit,' Han told Gizmodo. 'That's strange, only a larger companion can do this.'
In binary systems, a millisecond pulsar is usually accompanied by a white dwarf: a hot, dense core left behind after a star like our Sun has exhausted its fuel. But the data Han and his colleagues collected indicated that this companion had to lie somewhere in between a compact object and a normal star, he said.
Further investigation of this strange companion revealed that it is roughly as massive as our Sun, but it couldn't be a normal star because it was undetectable in all wavelengths outside of the radio spectrum. This led the researchers to conclude that it's a star stripped clean of its hydrogen, leaving behind a core primarily composed of helium. They published their findings today in the journal Science.
This type of binary system 'has never been discovered before,' Han said. But it has long been theorized that such a pairing could form via common envelope evolution, and he and his colleagues believe that's what happened here.
'The process of common envelope evolution is slightly different to how stars like pulsars are often thought to interact in binary systems,' Duncan Lorimer, a professor of physics and astronomy at West Virginia University who was not involved in the study, told Gizmodo in an email.
Normally, a neutron star's intense gravitational field pulls material from a companion star that has expanded, allowing its gaseous outer layers to be 'eaten' by the neutron star, he explained. This process, called accretion, causes the neutron star to 'spin up' and become a pulsar.
But in common envelope evolution, 'the companion star is so large that its outer layers engulf the neutron star as well,' Lorimer said. 'This acts as a brake on the whole binary system.'
Inside the companion star's outer layers—the envelope—friction causes the pulsar and the companion's core to spiral toward each other, forming a highly compact binary system, like the one Han and his colleagues have now observed. With an orbital period of just 3.6 hours, this pulsar and its companion are circling each other very closely.
Ultimately, the outer layers of the companion star are expelled, Lorimer said, which explains why this millisecond pulsar's helium star companion has been stripped.
'The evolutionary pathway that the authors set out, it's not a surprising pathway,' Victoria Kaspi, a professor of physics at McGill University who was not involved in the study, told Gizmodo. 'It's one that has been recognized, identified, discussed in detail for many years.'
'The interesting question is, if you're going to find 1,000 millisecond pulsars, what fraction of them will be like this one? It's about one in 1,000—something like that. And they found it,' she said.
Han and his colleagues believe there are more than a dozen other systems like this one in our galaxy, making them exceptionally rare. The fact that these researchers found one of them is a 'great breakthrough,' Lorimer said.
'The more millisecond pulsars we find, the more likely we are to find examples of rare evolutionary outcomes. This system is an excellent example of that,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
5 hours ago
- CNBC
It's not just AI — China's quickly gaining an edge over the U.S. in biotech
BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China's rapid rise in biotechnology, especially for drug and agricultural development. Out of five critical tech sectors, "China has the most immediate opportunity to overtake the United States in biotechnology," the Harvard Belfer Center for Science and International Affairs said Thursday in its release of a "Critical and Emerging Technologies Index," covering AI, biotech, semiconductors, space and quantum. While the U.S. is still the leader in all five, "the narrow U.S.-China gap [in biotech] suggests that future developments could quickly shift the global balance of power," the report said. The assessment echoes growing concerns in Washington. In fact, the U.S. National Security Commission on Emerging Biotechnology struck a more urgent tone in an April report, citing two years of research. "There will be a ChatGPT moment for biotechnology, and if China gets there first, no matter how fast we run, we will never catch up," the bipartisan Congressional commission said in the report, referring to the transformative chatbot released by U.S.-based OpenAI. "Our window to act is closing. We need a two-track strategy: make America innovate faster, and slow China down," the commission said. It recommends that the U.S. government spend at least $15 billion over the next five years to support the domestic biotech sector. China's biotech industry has evolved to the point that U.S. and European pharmaceutical giants in the last several months have spent billions to acquire China-developed drugs that could treat cancer if commercialized with regulatory approval. In March, British pharmaceutical giant AstraZeneca announced it will invest $2.5 billion in a research and development center in Beijing. The Harvard Belfer Center pointed out that China's biotech strengths stem from its "dominance in pharmaceutical production and manufacturing," in addition to having more human talent than the U.S. China also has a "more flexible regulatory regime and the ability to push things out faster," Cynthia Y. Tong, one of the Harvard report's authors, told CNBC in an interview Thursday. She noted that the U.S. tends to have a longer approval process, as well as more drawn out research and development period. And just as China is developing its biotech sector, reports from the U.S. biotech hub of Cambridge and Boston are revealing layoffs and empty labs. China has long used multi-year plans and preferential state policies to encourage the development of key technologies. Biotech is no different, gaining high-level support back in 2007. "Currently, the U.S. government has no cohesive, intentional biotechnology strategy, while China is gaining ground thanks to its aggressive and carefully coordinated state-led initiatives," the U.S. security commission said. The worry is that just as Chinese restrictions on rare earths start to hit car manufacturers, Chinese dominance in biotech could become yet another form of leverage for Beijing over the U.S. and other countries. "The likelihood there's going to be cooperation [between the] U.S. and China on anything is very low, in some ways least likely on biotech and AI" because of the congressional report, said Eric Rosenbach, director of the defense, emerging technology, and strategy program at Harvard's Belfer Center. He was chief of staff at the U.S. Department of Defense from 2015 to 2017. He expects more U.S. pressure on China. It remains to be seen what that would mean in practice for businesses — though some say the future of biotech development is inherently global. Insilico Medicine, a startup using AI to cut drug discovery costs, relies on a global team spread across China, North America and the Middle East, according to its founder and CEO Alex Zhavoronkov. On Tuesday, the company announced with a paper in Nature Medicine that it was the first to see successful clinical testing with an AI-discovered drug. While Insilico's AI work typically happens in Canada and Abu Dhabi, the chemical testing and experiments are done in China, Zhavoronkov said, adding that the head of clinical development is in Boston. He declined to comment on a commercialization timeline in light of conversations with regulators. Other data shows that China has surpassed the U.S. in the number of clinical trials conducted, seen significant patent growth and boasts the most life sciences construction activity in the world. China-based Capital O venture partner Yang Fan, who previously worked in the pharmaceutical industry, said he expects the best biotech companies of the future will navigate different countries' regulations and use resources across the globe, if not benefit from arbitrage opportunities given different requirements and cost of entry in various markets. "The Chinese market is like a big supermarket for anything that can be commoditized, AI or biotechnology," he said, adding that new startups in China have to be "really good" to stand out. As AI drives innovation costs down, Fan predicts that in biotech, "the real DeepSeek moment is probably going to happen in five years."

Epoch Times
6 hours ago
- Epoch Times
Milky Way's Chance of Colliding With Galaxy Billions of Years From Now? New Study Puts Odds at 50-50
CAPE CANAVERAL, Fla.—It turns out that looming collision between our Milky Way and Andromeda galaxies might not happen after all. Astronomers reported Monday that the probability of the two spiral galaxies colliding is less than previously thought, with a 50-50 chance within the next 10 billion years. That's essentially a coin flip, but still better odds than previous estimates and farther out in time.


Bloomberg
7 hours ago
- Bloomberg
Golden Dome Is a Chance for Superpowers to Make Space Safer
It's hardly surprising that some of the loudest objections to the Pentagon's proposed ' Golden Dome ' missile shield have come from Russia and China, who warn the system will spur a new nuclear arms race. Instead of minimizing such concerns, the US should leverage them to forge rules that will make space safer for everyone. Talks about establishing norms of behavior in space have been stalled for years at the United Nations, as Russia and China have pushed instead for a legally binding treaty banning the deployment of weapons in orbit. Golden Dome helps explain why. Traditionally, space-based missile defense has been considered destabilizing because it encourages adversaries to build up their arsenals in response, and because a truly successful shield could encourage the US to launch a nuclear first strike, confident it could deflect any counterattack.